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1. Introduction
Insulin is mainly known for its peripheral effects on the metabolism of glucose, fats, and
proteins. Following the discovery of insulin by Banting and Best in 1921, major research
works focused on the role  of  insulin in the peripheral  tissues (liver,  muscle  and adipo‐
cytes) in regulating glucose homeostasis. During the last two decades, evidence has accu‐
mulated  that  insulin  also  exerts  important  actions  within  the  central  nervous  system
(CNS) and peripheral  nervous system (PNS).  Although neurons are not  insulin-depend‐
ent,  they are insulin-responsive (Benedict et al.,  2004, 2011; de la Monte 2009, 2012; Lar‐
on 2009; Stockhorst et al., 2004; van der Heide et al., 2006).
Insulin acts as a neuropeptide in the brain to regulate food intake,  body weight,  mood,
cognitive  function,  memory,  neuronal  survival  and  synaptic  plasticity  (Laron,  2009;
Stockhorst  et  al.,  2004).  Conversely,  dysregulated insulin  receptor  signaling (e.g.  insulin
deficiency and insulin resistance)  in  the brain is  involved in the neurodegenerative dis‐
ease, dementia and mood disorders (Craft and Watson, 2004; de la Monte. 2012; Rasgon
& Kenna,  2005).  Interestingly,  intranasal  insulin  administration  has  an  improving  effect
of learning and memory as well as mood stabilizing effect in the patients with Alzheim‐
er’s  disease  (AD) and healthy volunteers  (Benedict  et  al.,  2004,  2007;  Reger  et  al.,  2006,
2008).  Based on these  findings,  novel  hypothesis  “Type 3  diabetes”  has  been proposed:
insulin resistance in the brain causes AD (de la Monte & Wands, 2008; de la Monte 2012;
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Steen et al., 2005). Thus, insulin receptor signaling attracts attention as the molecular tar‐
get for the treatment of cognitive and mood disorders.
In the present  review, we would like to  summarize the novel  biological  and pathophy‐
siological roles of neuronal insulin in health and disease.  In addition, we also introduce
several  of  our findings that  modulation of  neuronal  insulin receptor signaling by thera‐
peutic  drugs  and  bioactive  agents  via  multiple  mechanisms  in  cultured  bovine  adrenal
medullary chromaffin cells (embryologically derived from neural crest) ;  1) enhancement
of insulin receptor signaling by nicotine (Sugano et al.,  2006);  2) reduction of insulin re‐
ceptor  signaling  by  immunosuppressants  (cyclosporine  and tacrolimus)  (Shiraishi  et  al.,
2001: Satoh et al., 2008), ketone body acetoacetate (Yokoo et al., 2003), heat shock protein
90  (Hsp90)  inhibitors  (Saitoh  et  al.,  2002;  Yoshikawa  et  al.,  2010);  3)  negative-feedback
regulation  of  insulin  receptor  signaling  by  insulin  and  glycogen  synthase  kinase-3
(GSK-3)  inhibitors  (lithium  and  valproic  acid)  (Yokoo  et  al.,  2007;  Nemoto  et  al.,  2006,
2009) ; 4) neurite-like outgrowth induced by insulin (Nemoto et al., 2011), and up-regula‐
tion  of  cell  surface  voltage-dependent  Na+  channel  induced  by  insulin,  insulin-like
growth factor-1  (IGF-1)  and GSK-3  inhibitors  (lithium and valproic  acid)  (Yamamoto et
al., 1996, 1997; Yanagita et al., 2009, 2011).
2. Insulin and insulin receptor signaling in the brain
It  is  now  generally  thought  that  little  or  no  insulin  is  produced  in  the  brain  itself
(Woods, 2003; Banks, 2004; Laron 2009). Insulin crosses the blood-brain barrier (BBB) and
enters  the  brain  via  a  receptor-mediated  active  transport  system  (Baskin  et  al.,  1987;
Baura et al., 1993).
Insulin receptor is distributed in a widespread, but selective, pattern in the brain, includ‐
ing the  olfactory bulb,  hypothalamus,  hippocampus,  cerebellum,  amygdale  and cerebral
cortex (Marks et al., 1990; Unger & Betz, 1998). The expression level of the insulin recep‐
tor  is  developmentally  regulated,  being  higher  at  early  stages  and  lower  in  the  adult
(Chiu  & Cline  2010).  Brain  insulin  receptors  are  present  in  particularly  high  concentra‐
tions  in  neurons,  and in  much lower  levels  in  glia  (Schwartz  et  al.,  1992;  Unger  et  al.,
1989).  Subcellularly,  the  insulin  receptor  is  a  component  of  synapses,  where  it  concen‐
trates at the postsynaptic density (Abbott et al., 1999; Marks et al., 1988). Cell surface in‐
sulin receptor, a member of receptor tyrosine kinase family, consists of two extracellular
α- and two transmembrane β-subunits (~135 and ~95 kDa, respectively) that are encoded
by the same gene and derived from the single-chain insulin receptor precursor molecule.
The brain insulin receptor differs from its peripheral counterpart by having a lower mo‐
lecular  weight  of  both  α-  and β-subunits  (Heidenreich  et  al.,  1983).  This  is  presumable
the  result  of  alternative  mRNA  splicing  and  differences  in  receptor  glycosylation  (Hei‐
denreich et al.,  1983; Goldstein & Dudley, 1992; Sugimoto et al.,  2000).  As shown in fig.
1,  insulin  receptor  precursor  undergoes  translational  glycosylation,  intrachain  disulfide-
bond formation/isomerization (rearrangement),  and disulfide-linked homodimerization at
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the  endoplasmic  reticulum (ER).  The  homodimeric  insulin  receptor  precursor  is  proteo‐
lytically  processed  at  the  trans-Golgi  network  into  the  disulfide-linked  α2β2  complex,
which is transported to plasma membrane (reviewed in Wada et al., 2005). Binding of in‐
sulin to the α-subunit causes autophosphorylation of the β-subunit tyrosine residues. Ty‐
rosine  phosphorylation  of  β-subunits  induces  specific  recruitment  of  Src  homology  2
(SH2) and phosphotyrosine-binding (PTB) domain containing proteins (SH2 and PTB do‐
mains  are  domains  that  recognize  phosphorylated  tyrosine  residues).  The  most  promi‐
nent scaffold proteins recruited to the insulin receptor are the insulin receptor substrate
(IRS)-1/-2 and SHC (White, 1997, 1998). These scaffold proteins link the activated insulin
receptor to downstream signal transduction pathways.  Insulin binding to the insulin re‐
ceptor  activates  two  major  parallel  signal  transduction  cascades  identified  as  the  phos‐
phoinositide  3-kinase  (PI3K)/phosphoinositide-dependent  kinase  1  (PDK-1)/Akt  pathway
and  the  Ras/extracellular  signal-regulated  kinase  (ERK)  pathway  (van  der  Heide  et  al.,
2006: Wada et al., 2005). Akt catalyzes inhibitory Ser21/Ser9-phosphorylation of GSK-3α/3β
(Jope & Johnson, 2004; Jope et al., 2007).
3. Physiological roles of insulin in the brain
The neuronal specific insulin receptor knockout (NIRKO) mice study revealed that insu‐
lin receptor signaling in the CNS plays an important role in regulation of energy dispos‐
al,  fuel  metabolism,  and  reproduction:  the  inactivation  of  the  insulin  receptor  had  no
impact  on  brain  development  or  neuronal  survival.  However,  female  NIRKO  mice
showed increased food intake,  and both male and female  mice developed diet-sensitive
obesity with increases in body fat  and plasma leptin levels,  mild insulin resistance,  ele‐
vated  plasma insulin  levels,  and  hypertriglyceridemia.  NIRKO mice  exhibited  impaired
spermatogenesis  and  ovarian  follicle  maturation  because  of  hypothalamic  dysregulation
of luteinizing hormone (Brüning et  al.,  2000).  The NIRKO mice also had an impairment
of  the  counter-regulatory  response  to  hypoglycaemia  (Fisher  et  al.,  2005).  The  NIRKO
mice exhibit a complete loss of insulin-mediated activation of PI3K and inhibition of neu‐
ronal apoptosis. In intact animals, this loss results in markedly reduced phosphorylation
of  Akt  and  GSK-3β,  leading  to  substantially  increased  phosphorylation  of  the  microtu‐
bule-associated  protein  Tau,  a  hallmark  of  neurodegenerative  diseases.  Nevertheless,
these  animals  exhibit  no alteration in  neuronal  proliferation/survival,  memory (Schubert
et  al.,  2003).  Interestingly,  the early postnatal  inhibition of  brain insulin receptor  by us‐
ing small  interfering RNA causes structural  and functional  abnormalities  (e.g.  cerebellar
hypofoliation and hypotrophy, impaired motor function, and altered expression of neuro‐
trophins and neurotropin receptors) that resemble effects of fetal alcohol spectrum disor‐
der  (FASD).  The  findings  suggest  that  major  abnormalities  in  brains  with  FASD  are
mediated by impairments  in  insulin/IGF signaling.  (de  la  Monte  et  al.,  2011).  Although
there is  little evidence to date from neuronal insulin receptor knockout and knockdown
studies  for  a  key role  in  learning and memory,  there is  evidence that  insulin may play
important  roles  in  learning  and memory (Williamson et  al  2012).  The  deletion  of  IRS-2
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(but not IRS-1) causes a similar phenotype; IRS-2 knockout mice displayed hypothalamic
female infertility,  and increased food intake and obesity (Burks et  al.,  2000).  These find‐
ings  implicate  that  neuronal  insulin  receptor  ~  IRS-2  pathway plays  crucial  roles  in  the
neuroendocrine regulation of reproduction and energy homeostasis. Furthermore, the dis‐
ruption  of  the  IRS-2  gene  reduced  neuronal  proliferation  during  development  by  50%,
which  dissociated  brain  growth  from  IRS-1-dependent  body  growth.  In  the  old  IRS-2
knockout mice, neurofibrillary tangles containing phosphorylated tau accumulated in the
hippocampus,  suggesting that  IRS-2 signaling is  neuroprotective.  Thus,  dysregulation of
the IRS-2 branch of the insulin/IGF-1 signaling cascade reveals a molecular link between
diabetes  and neurodegenerative  disease  (Schubert  et  al.,  2003).  Indeed,  intravenous  and
intranasal administrations of insulin improve cognitive performance in a humans and an‐
imals in a wide variety of settings, including healthy subjects, aged subjects, AD patients
and in the various experimental models of insulin resistance (Reagan 2007; Stockhorst et
al., 2004: Wada et al., 2005; Watson & Craft, 2004).
4. Insulin resistance and cognitive disorders
The intensively studied phenomenon of insulin resistance in peripheral tissues is tightly
linked with overweight and a hallmark in the development of type 2 diabetes mellitus
(T2DM). Insulin resistance and impaired glucose tolerance are considered early warning
signs for the development of T2DM. Cognitive impairments are more common in diabetic
patients than in non-diabetic subjects. In the Rotterdam study, of 6,370 elderly subjects stud‐
ied for 2.1 years, 126 developed dementia; 89 of these were specifically diagnosed with AD.
T2DM doubled the risk of a patient having dementia and patients on insulin had four times
the risk (Ott et al., 1999). Hisayama Study in Japan also revealed that impaired glucose toler‐
ance (an early warning sign of T2DM) increased risk of all-cause dementia (Ohara et al.,
2011). This T2DM-associated dementia is in part due to ischemic events resulting from cere‐
bral microvascular and/or macrovascular disease or to repeated episodes of severe hypogly‐
cemia. These conditions have been referred to as secondary diabetic encephalopathy.
However, there is accumulating evidence suggesting that cognitive dysfunction is also
caused by diabetic dysmetabolism in the brain, so-called primary diabetic encephalopathy
(Ott et al., 1999; Sima et al., 2004; Sima & Li. 2006).
Cerebral insulin resistance could be the result of various mechanisms at different levels.
Acute elevations of plasma insulin levels have been found to correlate with cerebro-spinal-
fluid (CSF) insulin concentrations in healthy, normal weight humans. However, in over‐
weight humans, the ratio of CSF to plasma insulin seems altered – elevated plasma insulin
levels due to peripheral insulin resistance are not accompanied by similar elevations in cere‐
bral insulin levels (Ketterer et al., 2011).
The peripheral and CNS insulin abnormalities have been reported in AD patients. AD pa‐
tients have an increased risk for hyperinsulinemia and hyperglycemia relative to healthy
controls (Meneilly et al., 1993; Razay and Wilcock, 1994), and also have lower CSF insulin
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levels, higher plasma insulin levels, and reduced insulin-mediated glucose disposal, a pat‐
tern consistent with insulin resistance (Craft et al., 1999; Watson & Craft 2006). AD brains
show reduced insulin receptor density and tyrosine kinase activity markers (Frölich et al.,
1998). The expression of insulin receptor was increased in the hippocampal dentate gyrus
and CA1 field following training of rodents on a spatial memory task, suggesting that neu‐
ronal insulin sensitivity could be enhanced during learning (Zhao et al., 1999). In addition,
intravenous and intranasal administrations of insulin improve cognitive performance in AD
patients and in the experimental models of insulin resistance (Wada et al., 2005; Watson &
Craft, 2004). Taken together, these correlative findings suggest that insulin resistance in the
brain may be associated with AD.
Moreover, de la Monte et al., proposed novel disease concept “Type 3 diabetes”: AD is a
brain DM (Steen et  al.,  2005;  de  la  Monte  and Wands,  2008).  Postmortem brain studies
demonstrated  that  the  molecular,  biochemical,  and  signal  transduction  abnormalities  in
AD  are  virtually  identical  to  those  that  occur  in  T1DM  and  T2DM  (see  review  de  la
Monte & Wands,  2008;  de la Monte 2012).  In addition,  experimental  brain diabetes pro‐
duced by intracerebral administration of streptozotocin shares many features with AD, in‐
cluding  cognitive  impairment  and  disturbances  in  acetylcholine  homeostasis.  This
experimental brain diabetes is treatable with insulin sensitizer agents, i.e., drugs currently
used to treat T2DM (de la Monte & Wands, 2008).
5. Insulin resistance and mood disorders
Evidence has accumulated that obesity is associated with mood disorders. Obesity is associ‐
ated with an approximately 25% increase in odds of mood and anxiety disorders and an ap‐
proximately 25% decrease in odds of substance use disorders (Simon et al. 2006). The
individuals meeting criteria for obesity are more likely to report a major depressive episode
in the past 12 months when compared to healthy weight individuals (Chen et al. 2009). Pro‐
spective studies add further evidence that obesity is a significant risk factor for depression,
although depression did not increase the risk of future obesity (Roberts et al. 2003).
Numerous  studies  describe  the  association  between  insulin  resistance  and  depression.
Low glucose utilization rates as well as abnormal glucose and insulin disposal rates have
been reported in a significant proportion of patients with depressive disorders (Ramasub‐
bu 2002; Rasgon & Kenna 2005).  The evidence lending support to this association is the
influence of therapeutic drugs for depression (e.g.  selective serotonin-reuptake inhibitors
(SSRIs) and tricyclic antidepressants) on insulin resistance. Improvement in insulin resist‐
ance has been reported with successful treatment of depression with SSRIs,  but worsen‐
ing  of  insulin  resistance  has  been  reported  with  tricyclic  antidepressants  (Rasgon  &
Kenna 2005; Sockynska et al.,  2011).  Furthermore, hyperinsulinemia, a feature of periph‐
eral insulin resistance, may in part be responsible for decreased appetite and weight loss
observed in depressive disorders (Licinio-Paixao, 1999).
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Although precise  mechanisms that  insulin  resistance induces  mood disorder  are  not  re‐
vealed,  impairment  of  multi-neuroregulatory functions of  insulin  (e.g.  CNS glucose me‐
tabolism,  BBB  transport  and  neuroprotective  effect)  caused  by  insulin  resistance  in  the
brain  may  contribute  to  evolution  and  progression  of  serious  mental  disorders  includ‐
ing depression (Ramasubbu 2002).
6. Intranasal administration of insulin
Intranasal  delivery  is  a  noninvasive  method of  bypassing  the  BBB to  deliver  therapeu‐
tic  agents  to  the  brain  and  spinal  cord.  The  use  of  intranasal  administration  to  target
therapeutics  to  the  CNS  has  many  benefits  (safety,  cost,  and  easy  handling)  in  the
treatment  of  neurologic  disorders,  and has been used to target  a  wide variety of  thera‐
peutics  to  the  CNS  [e.g.  Nerve  growth  factor  (Chen  X-Q  et  al.,  1998),  IGF-1  (Thorne
RG  et  al.,  2004),  glucagon-like  peptide-1  antagonist,  exendin9–39  (Banks  WA  et  al.,
2004)  and carbamazepine (Barakat  NS et  al.,  2006)].  Intranasal  administration of  insulin
provides  direct  access  of  the  hormone  to  the  CSF  within  30  min  without  substantial
uptake  into  the  bloodstream  (Born  et  al.,  2002).  Direct  delivery  of  therapeutics  from
the  nose  to  the  brain  was  initially  attributed  to  the  olfactory  pathway  (Thorne  et  al.,
1995).  More  recently,  the  contribution  made  by  the  trigeminal  pathway  to  intranasal
delivery  to  the  CNS  has  also  been  recognized  (Thorne  RG  et  al.,  2004).  Because  intra-
neuronal  transport  of  neuropeptides  from  the  nasal  cavity  to  the  olfactory  bulb  takes
several  hours  (Thorne  et  al.,  1995),  extra-neuronal  passage  through  intercellular  clefts
of  the  olfactory epithelium is  assumed to  be  the  preferential  pathway of  peptide  trans‐
port  into the CNS compartment (Ott  et  al.,  2012).
Intranasal  insulin  improves  memory  function  both  in  healthy  humans  and  AD  pa‐
tients.  Chronic  (8  weeks)  administration  of  intranasal  insulin  in  cognitively  normal
young  adults  is  associated  with  increased  memory  performance  (Benedict  et  al.,  2004,
2007).  Intranasal  insulin  has  also  been  studied  in  cognitively  impaired  patients.  Intra‐
nasal  insulin  treatment  produced  significant  memory  improvement  in  memory-im‐
paired  subjects  (early  stage  AD  or  amnestic  mild  cognitive  impairment)  (Reger  et  al.,
2006,  2008).  Interestingly,  memory-improving  effects  of  intranasal  insulin  were  found
only in non-carriers  of  the APOE4 gene allele  that  is  linked to  an increased risk of  de‐
veloping AD (Cummings  and Cole,  2002),  whereas  the  APOE4-postive  subjects  showed
no  benefits  or  even  a  decline  in  memory  function  (Reger  et  al.,  2006).  In  addition,  in‐
tranasal  insulin  administration  to  obese  males  over  8  weeks  caused  improvement  of
declarative  memory  and  mood  without  reduction  in  body  weight  and  fat  (Hallschmid
et  al.,  2008).  Thus,  the enhancement of  insulin signaling in the CNS by intranasal  insu‐
lin  administration  may  be  a  useful  approach  in  the  treatment  and/or  prevention  of
cognitive and mood dysfunction.
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7. Modulation of neuronal insulin receptor signaling by therapeutic
drugs and bioactive agents.
There are two major approaches to improve insulin signal impairment: 1) stimulation of in‐
sulin receptor signaling by insulin such as intranasal administration of insulin, and 2) ad‐
justment of insulin receptor signaling via modulation of expression and function of insulin
receptor signaling molecules. We have previously reported that several therapeutic drugs
and bioactive agents affect cell surface density of insulin receptor and protein levels of
IRS-1, IRS-2 and other various downstream signaling molecules via multiple intracellular
mechanisms in cultured bovine adrenal medullary chromaffin cells. In this part, we would
like to introduce several of our findings that the modulation of neuronal insulin receptor
signaling by therapeutic drugs and bioactive agents (Fig. 1).
7.1. Nicotine and protein kinase C-α (PKC-α) activation: enhancement of insulin receptor
signaling via increase in IRS-1, IRS-2, and cell surface insulin receptor (Fig.1 ① and ①').
Activation  of  neuronal  nicotinic  acetylcholine  receptors  (nAChRs)  enters  Na+  into  the
cells  and rapidly  evokes  excitatory  postsynaptic  potentials  and Ca2+-dependent  exocyto‐
sis  of  neurotransmitters,  while  generating  longer-lasting  multiple  effects  (e.g.  synaptic
plasticity,  learning  and  memory,  and  cell  survival)  (Dajas-Bailador  &  Wonnacott  2004;
Sugano  et  al.,  2006).  The  aberrant  down-regulation  of  nAChRs  accounts  for  cognitive
deficits  in  normal  aging  and  age-related  neurodegenerative  diseases,  such  as  AD  (Pic‐
ciotto  &  Zoli  2002),  with  impairment  of  acetylcholine  synthesis  in  AD  brain  (Hoshi  et
al.  1997).  Enhancement  of  nAChRs  signaling  caused  by  choline  esterase  inhibitors  is
the  major  therapeutic  strategy  against  these  cognitive  impairments,  but  the  therapeutic
mechanisms  have  not  been  fully  identified  at  the  cellular  level  (Newhouse  et  al.  2001;
Nordberg 2001;  Picciotto and Zoli  2002).
In cultured bovine adrenal  chromaffin cells  treated with nicotine (10 μ M for 24 h),  in‐
sulin  (100  nM  for  10  min)-induced  phosphorylation  of  Akt,  GSK-3β  and  ERK1/2  was
enhanced  by  ~62%,  without  altering  levels  of  these  protein  kinases.  Treatment  with
nicotine  produced  time  ( ≧  12  h)-  and  concentration  (EC50  =  3.6  and  13  μ  M)-depend‐
ent  increases  in  IRS-1  and IRS-2  levels  by  ~125  and 105%,  without  altering  cell  surface
density  of  insulin  receptor.  Nicotine  also  increased  IRS-1  and  IRS-2  mRNA  levels  by
~57  and ~50%.  Nicotine-induced increase  in  IRS-1  and IRS-2  was  prevented  by  nAChR
antagonists  (d-tubocurarine and mecamylamine),  cell  membrane-permeable  Ca2+  chelator
(BAPTA-AM),  protein synthesis  inhibitor  (cycloheximide),  transcription inhibitor  (actino‐
mycin  D),  conventional  protein  kinase  C  (cPKC)  inhibitor  (Gö6976),  or  ERK  kinase  in‐
hibitor  (PD98059  and  U0126).  Nicotine  phosphorylated  cPKC-α,  thereby  increasing
phosphorylation  of  ERK1/ERK2,  as  demonstrated  by  using  Gö6976,  PD98059  or  U0126.
Selective  activation  of  cPKC-α by  thymeleatoxin  mimicked  these  effects  of  nicotine.  In‐
terestingly,  activation  of  PKC-α  by  thymeleatoxin  or  other  phorbol  esters  up-regulated
cell  surface  insulin  receptor  via  transcriptional/translational  events  (Yamamoto  et  al.,
2000),  although  nicotine  did  not  affect  cell  surface  insulin  receptor.  Thus,  stimulation
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of  nAChRs  up-regulates  expression  of  IRS-1/IRS-2  via  Ca2+  -dependent  sequential  acti‐
vation  of  cPKC-α  and  ERK,  and  enhances  insulin-induced  PI3K/Akt/GSK-3β  and  ERK
signaling  pathways  (Sugano  et  al.,  2006).  This  nicotine-induced  enhancement  of  insulin
receptor  signaling may contribute to  the neuroprotective effects  of  nicotine.
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Figure 1. Modulation of insulin receptor signaling by therapeutic drugs and bioactive agents via multiple intracellular
mechanisms in adrenal chromaffin cells. ① and ①’: Nicotine-induced up-regulation of IRS-1 and IRS-2, and PKC-α acti‐
vation-induced up-regulation of insulin receptor (see 7-1).②: Immunosuppressants (cyclosporine and tacrolimus)-in‐
duced down-regulation of cell surface insulin receptor and IRS-2 (see 7-2).③: Acetoacetate-induced down-regulation
of insulin receptor.④: Hsp90 inhibition-induced impairment of insulin receptor signaling via down-regulation of cell
surface insulin receptor and various downstream signaling molecules (e.g. IRS-1, PI3K, PDK-1, Akt, GSK-3β, and Raf-1)
(see 7-4). ⑤ and ⑤’: GSK-3β-mediated negative feedback regulation of insulin receptor signaling caused by chronic
treatment with insulin and GSK-3 inhibitors (lithium and valproic acid) (see 7-5).
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7.2. Immunosuppressants, cyclosporine and tacrolimus: reduction of insulin receptor
signaling via down-regulation of cell surface insulin receptor and IRS-2. (Fig.1②)
Cyclosporine  (Cyclosporin  A)  and  tacrolimus  (FK506)  are  clinically  important  immuno‐
suppressive drugs that  are  widely used to  prevent  organ rejection after  transplantation.
In addition,  an increasing number of autoimmune diseases are treated with these drugs
(Oetjen et al.,  2003).  Both structurally distinct drugs bind to their respective intracellular
receptors,  the  immunophilins,  and the  drug-immunophilin  complexes  then  bind  to  and
inhibit  calcineurin  phosphatase;  this  inhibition  of  calcineurin  is  well  known  as  the
mechanism of immunosuppressive effect  (Ho et  al.,  1996).  In addition,  cyclosporine and
tacrolimus directly  inhibit  peptidyl  prolyl  cis-trans  isomerase  (PPIase)  activity  of  immu‐
nophilin (Shiraishi  et  al.,  2000).  Among the most  serious adverse effects  of  cyclosporine
and  tacrolimus  are  the  impaired  glucose  tolerance  leading  to  hyperglycemia  and  DM
(Kahan, 1989, 1994; Jindal et al.,  1997; Saltiel,  2001; Oetjen et al.,  2003) as well as neuro‐
toxicity  (Bechstein  2000;  Gijtenbeek  et  al.,  1999).  The  incidence  of  glucose  tolerance  has
been estimated to be 10 to 30% (Kahan, 1989; Jindal et al.,  1997; Oetjen et al.,  2003).  Be‐
tween 10~28 % of patients who receive cyclosporine experience some form of neurotox‐
ic  adverse  event.  Mild  symptoms  are  common  and  include  tremor,  neuralgia,  and
peripheral  neuropathy.  Severe  symptoms affect  up to  5  % of  patients  and include psy‐
choses,  hallucinations,  blindness,  seizures,  cerebellar  ataxia,  motoric  weakness,  or  leu‐
koencephalopathy.  The  mechanisms  of  neurotoxicity  associated  with  cyclosporine  and
tacrolimus are less well-understood (Bechstein 2000; Gijtenbeek et al.,  1999).
Chronic  (≧ 3  h)  treatment  of  cultured bovine adrenal  chromaffin  cells  with cyclosporin
A  or  FK506  selectively  decreased  IRS-2  protein  level  by  w50%  (IC50  =  200  or  10  nM),
without changing IRS-2 mRNA level, and protein levels of insulin receptor, IGF-1 recep‐
tor,  IRS-1,  PI3K /  PDK-1 /  Akt /  GSK-3β and ERK1 /  ERK2 via inhibition of  calcineurin
activity  (IC50  =  500  or  40  nM,  in  vitro  assay).  Cyclosporin  A  and  FK506  accelerated
IRS-2 degradation rate (t1/2)  from >24 to ~4.2 h,  without altering IRS-2 protein synthesis.
IRS-2  reduction induced by cyclosporin  A or  FK506 was  prevented by lactacystin  (pro‐
teasome  inhibitor),  but  not  by  calpeptin  (calpain  inhibitor)  or  leupeptin  (lysosome  in-
hibitor).  Cyclosporin A or FK506 increased serine-phosphorylation and ubiquitination of
IRS-2.  These  results  suggest  that  calcineurin  inhibition  by  cyclosporin  A  or  FK506  de‐
creased IRS-2 protein level  via proteasomal IRS-2 degradation (Satoh et  al.,  2008).  Inter‐
estingly,  inhibition  of  PPIase  activity  of  immunophilin  by  cyclosporin  A  or  FK506
inhibits  externalization of  insulin  receptor  (but  not  IGF-1  receptor),  and down-regulates
cell  surface expression of  insulin receptor (Shiraishi  et  al.,  2000).  Cell  surface density of
IGF-1  receptor  was  not  changed  in  cyclosporin  A-  or  FK506-treated  cells;  however,
IGF-1-induced  phosphorylations  of  GSK-3β  and  ERK1/ERK2  were  attenuated  by  ~50%.
Therefore,  cyclosporin  A and FK506  reduced insulin  receptor  signaling  via  two mecha‐
nisms;  (1)  down-regulation  of  cell  surface  expression  of  insulin  receptor  via  inhibition
of  PPIase  activity  of  immunophilin,  and (2)  selective  reduction  of  IRS-2  protein  via  in‐
hibition of calcineurin. As mentioned above, knockout mice of insulin receptor,  IRS-1 or
IRS-2  study revealed that  neuronal  insulin receptor  ~  IRS-2  pathway plays  crucial  roles
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in  the  regulation  of  reproduction,  energy homeostasis,  cognitive  performance,  and neu‐
roprotection.  In  addition,  forebrain-specific  calcineurin  knockout  mice  exhibit  impair‐
ment  of  bidirectional  synaptic  plasticity,  working/episodic-like  memory,  and  multiple
abnormal  behaviors  related  to  schizophrenia  (miyagawa et  al.,  2003;  Zeng  et  al.,  2001).
Thus, this reduction of insulin receptor signaling might be involved in the neuronal dis‐
orders  caused  by  immunosuppressants.  Our  findings  raise  a  possibility  that  intranasal
insulin  administration  might  be  effective  in  the  treatment  for  immunosuppressants-in‐
duced neuronal disorders.
7.3. Ketone body acetoacetate: reduction of insulin receptor signaling via down-
regulation of cell surface insulin receptor. (Fig.1③)
It has been widely accepted that glucose is the main energy source in the brain. Howev‐
er,  in  some circumstances,  such as  diabetes,  starvation,  during the  suckling  period and
the ketogenic diet,  brain uses the ketone bodies,  acetoacetate and β-hydroxybutyrate,  as
energy  sources  (Massieu  et  al.,  2003;  Nehlig  &  Pereira  de  Vasconcelos,  1993).  Ketone
body utilization in brain depends mainly on its  blood concentration,  which is  normally
very low, but increases substantially during the conditions mentioned above (Massieu et
al.,  2003),  although astrocyte can produce ketone body (Guzmán & Blázquez 2004).  Un‐
der normal conditions, blood levels of ketone bodies are maintained below 0.5 mM (So‐
koloff,  1973),  but,  during  fasting  or  a  high-fat,  low-protein,  and  low-carbohydrate  diet,
blood  levels  of  ketone  bodies  become  elevated  (referred  to  as  ketosis)  (Massieu  et  al.,
2003; Noh 2006). Previous studies have demonstrated that, during starvation or adminis‐
tration of ketone bodies, the ketone bodies have neuroprotective effects against hypoxia /
ischemia- and glutamate-induced neuronal damage toxicity, AD, and Parkinson’s disease
(Maalouf et al.,  2009; Massieu et al.,  2003; Noh 2006).  Ketone bodies are converted from
free  fatty  acid  (FFA)  when  there  is  not  enough  insulin.  The  increased  level  of  FFA  is
linked to the insulin-resistance in DM and obesity because FFA interferes with insulin’s
intracellular  signaling  (Boden  et  al.,  2001;  Patti,  1999).  Diabetic  ketoacidosis  is  a  severe
and life threatening metabolic disease caused by an absolute or relative deficiency of in‐
sulin  (Wolfsdorf  et  al,  2009;  Yokoo et  al.,  2003).  Cerebral  edema is  the  most  important
neuronal  complication  of  diabetic  ketoacidosis  as  it  is  associated  with  a  high  mortality
rate of 20 to 90 %. Of the survivors, 20 to 40 % suffer from serious and permanent neu‐
rologic  disability  including motor  deficits,  visual  impairment,  seizure  disorder,  learning
disability and speech disturbance. Clinically, apparent cerebral edema occurs in approxi‐
mately 1% of episodes of diabetic ketoacidosis, and the pathogenesis of diabetic ketoaci‐
dosis-related  cerebral  edema  is  unclear  and  incompletely  understood  (Glaser  2009;
Shastry & Bhatia 2006; Wolfsdorf et al, 2009).
Chronic (≧ 24 h) treatment of cultured bovine adrenal chromaffin cells with ketoacidosis-
related concentrations (≧3 mM) of acetoacetate (but not β-hydroxybutyrate, acetone, and
acidic medium) caused a time- and concentration-dependent reduction of cell surface in‐
sulin  receptor  by ~38%.  Acetoacetate  decreased protein  and mRNA levels  of  insulin  re‐
ceptor  via  shortening  insulin  receptor  mRNA  half-life  (stability).  In  cells  treated  with
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acetoacetate  (10  mM,  24  h),  insulin-induced (100  nM for  10  min)  tyrosine-phosphoryla‐
tion  of  IRS-1  was  attenuated  by  56%  in  acetoacetate-treated  cells,  with  no  change  in
IRS-1 level. These results suggest that chronic treatment with ketoacidosis-related concen‐
trations of acetoacetate (but not β-hydroxybutyrate and acetone) down-regulated the den‐
sity of cell surface insulin receptor, thereby reducing insulin receptor signaling (Yokoo et
al.,  2003).  Further  in  vivo and in  vitro  investigations  are  required to  elucidate  the  rela‐
tionship  between  the  acetoacetate-induced  impairment  of  neuronal  insulin  receptor  sig‐
naling and the diabetic ketoacidosis-related neuronal damages.
7.4. Hsp90 inhibitors: impairment of insulin receptor signaling via down-regulation of
cell surface insulin receptor and various downstream signaling molecules. (Fig.1④)
Hsp90 is the most abundant molecular chaperone in eukaryotic cells (Welch and Feramisco,
1982). It has been increasingly recognized that Hsp90 plays a important role in the regulat‐
ing signal transduction pathways that control cell proliferation and cell death, since its chap‐
erone function is restricted to a subset of proteins including nuclear hormone receptors,
tyrosine kinases, serine/threonine kinases, and transcription factors (Kamal et al., 2004;
Richter and Buchner, 2001; Zhang and Burrows 2004). These findings were evidenced by us‐
ing selective Hsp90 inhibitors [geldanamycin (GA), 17-allylamino-17-demethoxy-geldana‐
mycin (17-AAG), Herbimycin A (HA) or radicicol] (Saitoh et al., 2002; Whitesell et al., 1994;
Yoshikawa et al., 2010). GA binds to the adenosine nucleotide binding site of N-terminal do‐
main of Hsp90 with affinity higher than that of ATP, inhibiting the ATPase activity/chaper‐
one function of Hsp90 (Whitesell et al., 1994; Young et al., 2001).
In adrenal chromaffin cells, inhibition of Hsp90 by GA or HA decreased cell surface 125I- in‐
sulin binding in a concentration- and time-dependent manner. GA (1 μM for 24 h) lowered
the Bmax value of 125I-insulin binding by 80%, without changing the Kd value. Western blot
analysis showed that GA (1 μM for 24 h) lowered α2β2 tetramer-form of insulin receptor
level by 83%, while raising insulin receptor precursor level by 100%. [35S]methionine/
cysteine pulse-chase study of insulin receptor revealed that monomeric insulin receptor pre‐
cursor (~190 kDa) developed into the homodimeric insulin receptor precursor (~380 kDa)
and the mature α2β2 insulin receptor (~410 kDa) in nontreated cells. In contrast, in GA-treat‐
ed cells, the homodimerization of monomeric insulin receptor precursor was completely
blocked. GA had no effect on insulin receptor mRNA levels and internalization rate of cell
surface insulin receptor. Thus, inhibition of chaperone activity of Hsp90 by GA completely
blocked homodimerization of monomeric insulin receptor precursor in the ER; the dimeric
insulin receptor precursor and the tetrameric mature-form of insulin receptor were signifi‐
cantly decreased, whereas the monomeric insulin receptor precursor was accumulated in
the ER. Chaperone activity of Hsp90 is indispensable to the homodimerization of monomer‐
ic insulin receptor precursor (Saitoh et al., 2002).
GA also affects the protein levels of downstream signaling molecules of insulin receptor.
GA treatment significantly decreased protein levels of IRS-1,  PI3K, PDK-1, Akt,  GSK-3β,
and Raf-1,  without altering protein levels of ERK and ERK kinase.  Interestingly,  GA in‐
creased protein level  of  IRS-2.  Chronic (≧12 h) treatment with 0.1–10 μM Hsp90 inhibi‐
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tor  (GA,  17-AAG,  HA,  and  radicicol)  decreased  IRS-1  level  by  ~66%,  while  increasing
IRS-2 level  by ~160%. These effects  of  GA (IC50  =  155 nM, EC50  =  177 nM) and 17-AAG
(IC50  =  310  nM,  EC50  =  260  nM)  were  time-  and concentration-  dependent.  GA-induced
decrease  of  IRS-1  was  attenuated  by  proteasome  inhibitors  (lactacystin,  β-lactone  or
MG132), but not by calpain inhibitor (calpastatin) or lysosome inhibitor (leupeptin). GA-
induced increase  of  IRS-2  was  prevented by cycloheximide  or  actinomycin  D.  GA low‐
ered  IRS-1  mRNA  level  by  ~39%,  while  raising  IRS-2  mRNA  level  by  ~109%,  without
changing the stability of IRS-1 and IRS-2 mRNA. Nuclear run-on assay revealed that GA
retarded IRS-1 gene transcription by 42%, while accelerating IRS-2 gene transcription by
41%. Hsp90 inhibitors oppositely altered IRS-1 and IRS-2 levels via proteasomal degrada‐
tion and gene transcription (Yoshikawa et al., 2010).
Increasing  evidence  has  accumulated  over  the  past  2  decades  that  anti-Hsp90  autoanti‐
bodies  in  CSF  may  be  involved  in  the  various  neuropsychological  diseases.  Aberrant
increase  in  anti-Hsp90  antibodies  in  CSF  or  blood  were  found  in  the  patient  with
Schizophrenia  (Kim et  al.,  2001),  autism (Evers  et  al.,  2002),  acute  bipolar  mania  (Shen
et  al.,  2006),  and  multiple  sclerosis  (Cid  et  al.,  2007).  The  autoantibodies  to  Hsp90  in
CSF  from  multiple  sclerosis  induced  cell  death  of  cultured  oligodendrocyte  precursor
cells  (Cid  et  al  2005).  Moreover,  it  has  been  reported  that  schizophrenia  associated
with  abnormalities  in  glucose  metabolism  that  may  lead  to  insulin  resistance  and  a  3-
fold  higher  incidence  of  T2DM  (Zhao  et  al  2006).  In  postmortem  brain  tissue  from
schizophrenic  patients,  protein  level  of  insulin  receptor  β-subunit  and  Akt  activity
were  drastically  decreased  (Zhao  et  al  2006).  These  correlative  findings  imply  that
chaperone  activity  of  Hsp90  plays  crucial  roles  in  the  regulation  of  various  neuropsy‐
chological  functions in brain via maintenance the expression and function of  insulin re‐
ceptor  and downstream signaling molecules.
A derivative  of  GA,  17-AAG,  has  similar  cellular  effects  of  GA but  lower  hepatotoxici‐
ty  than  GA.  17-AAG  exerts  a  potent  antitumor  activity  in  preclinical  models  and  is
currently  in  clinical  trials  (Neckers  2002).  Aberrant  expression of  IRS-1  has  been associ‐
ated  with  pathogenesis  and  progression  of  breast  cancer  and  prostatic  cancer  (Morelli
et  al.,  2003;  Reiss  et  al.,  2000;  Koda  2006).  In  breast  cancer,  IRS-1  overexpression  has
been associated with  tumor development,  hormone independence,  and anti-estrogen re‐
sistance  (Surmacz  2000).  In  hormone  dependent  breast  cancer  cell  lines,  the  expression
of  IRS-1 has been correlated with estrogen receptorα (ERα,  and numerous studies  have
demonstrated  that  IRS-1  is  one  of  the  central  elements  of  ERα-IGF-1  crosstalk  (Sur‐
macz  2000).  In  patients  with  primary  breast  cancer,  IRS-1  expression  is  correlated  with
poorly  differentiation  and  with  lymph  node  metastasis  (Koda  et  al  2006).  Human  pro‐
static  cancer  LNCaP cells  are  characterized by having a  frame-shift  mutation of  the  tu‐
mor  suppressor  gene  piedmont  triad  entrepreneurial  network,  low  levels  of  IGF-I
receptor  and no  IRS-1.  Reiss  et  al.  reported  that  ectopic  expression  of  IRS-1  in  LNCaP
cells  increases  cell  adhesion and decreases  cell  motility;  over-expression of  IGF-1  recep‐
tor,  in  the  absence  of  IRS-1,  causes  growth  arrest  and a  combination  of  IGF-1  receptor
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and  IRS-1  restores  the  transformed  phenotype  of  LNCaP  cells.  These  correlative  find‐
ings  indicated that  IRS-1  expression is  involved in  the  growth regulation of  breast  and
prostatic  cancer.  Thus,  the  decreasing  effect  of  17-AAG  on  the  IRS-1  could  be  contrib‐
uted  to  the  anti-tumor  effect  against  these  cancers,  although  our  results  were  obtained
from  primary  cultured  bovine  chromaffin  cells.  In  addition,  previous  studies  with
IRS-1  knockout  mice  or  the  cells  derived  from  these  mice  have  suggested  that  IRS-2
could  compensate  for  IRS-1  deficiency  more  effectively  in  liver  and  pancreatic  cells
than  in  skeletal  muscle,  fibroblasts,  or  adipocytes  (Tanemoto  et  al.  1994;  Bruning  et  al
1997;  Sesti  et  al.  2001).  It  has  been  shown  that  IRS-2  has  a  major  role  in  regulating
hepatic  glucose  production and in  controlling  pancreatic  cell  development  and survival
(Sesti  et  al.  2001).  Indeed,  IRS-2  knockout  mice  exhibit  insulin  resistance  with  abnor‐
mal  glucose  tolerance  at  birth  and  progressively  develop  fasting  hyperglycemia  as  a
result  of  inadequate compensatory insulin secretion because of  pancreatic  β-cell  apopto‐
sis  (Kubota  et  al.  2000;  Withers  et  al.  1998).  Thus,  the  increasing  effect  of  17-AAG  on
the IRS-2  expression would be convenient  for  avoiding side effects  such as  hyperglyce‐
mia,  insulin resistance,  and pancreatic  β-cell  damage,  during anti-cancer  therapy by 17-
AAG.  Therefore,  it  is  interesting  to  investigate  precisely  the  down-  and  up-regulation
of  IRS-1 /  IRS-2 by 17-AAG in the animal  model,  in  vivo  study.
7.5. Insulin, IGF-1 and potent GSK-3 inhibitors (lithium and valproic acid): negative
feedback regulation of insulin receptor signaling. (Fig.1 ⑤ and ⑤’)
Control  over  insulin  signaling  can  be  achieved  by  autoregulation,  whereby  insulin-
stimulated downstream components  (e.g.  Akt,  GSK-3β,  mTOR,  and ERK1/2)  inhibit  up‐
stream  elements  (negative  feedback  control;  autologous  regulation).  The  insulin
receptor  and  the  IRS  proteins  are  targets  for  these  feedback  control  mechanisms,  with
phosphorylation  of  IRS  proteins  on  Ser  /  Thr  residues  being  a  key  step  in  these  feed‐
back  control  processes.  For  example,  Ser  /  Thr-phosphorylation  of  IRS-1  caused  by
downstream signals  of  the PI3K pathway (e.g.,  mTOR) results  in  the self-attenuation of
IRS-1  activity.  Additionally,  signals  from  apparently  unrelated  (heterologous)  pathways
also  inhibit  insulin  signaling.  The  agents  inducing  insulin  resistance  (e.g.,  tumor  ne‐
crosis  factor-α)  increase Ser  /  Thr-phosphorylation of  IRS-1 via  activating protein kinas‐
es  (e.g.,  c-Jun  N-terminal  kinase)  and  caused  negative  feedback  regulation  of  insulin
receptor  signaling (Boura-Halfon & Zick 2009;  Copps & White.2012;  Zick 2001).
GSK-3, a serine/threonine protein kinase, is constitutively active in nonstimulated cells,
causing phosphorylation and inactivation/degradation of various signaling molecules (e.g.,
glycogen synthase), transcription factors (e.g., β-catenin), translation initiation factor eIF2B,
and structural proteins (e.g., tau) (Jope & Johnson, 2004; Jope et al., 2007; Meijer et al., 2004;
Nemoto et al., 2006). Insulin- or IGF-I-induced activation of Akt increases Ser21/Ser9 phos‐
phorylation of GSK-3α/-3β and inhibits catalytic activity of GSK-3α/-3β.
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In  adrenal  chromaffin  cells,  insulin  activated  insulin  receptor  but  not  IGF-1  receptor,
whereas  IGF-1  activated  both  insulin  receptor  and  IGF-1  receptor  (Yanagita  et  al.,
2011).  Insulin  treatment  increased  Ser9-phosphorylated  GSK-3β  level  by  47%  within  1
min,  with  peaking  to  104%  increase  at  1  h  and  declining  to  57%  increase  at  24  h
(Nemoto  et  al.,  2006).  IGF-1  (100  nM)  also  increased  Ser9-phosphorylated  GSK-3β  level
within 1  min,  and inhibited GSK-3β activity.  The maximum inhibition of  GSK-3β activ‐
ity  (~50%)  was  observed  at  1  min  after  treatment  with  100  nM  IGF-1,  and  inhibition
of  GSK-3β  activity  was  continued  for  up  to  24  h  (Yanagita  et  al.,  2011).  Inhibition  of
GSK-3β by  chronic  treatment  with  insulin,  IGF-1,  lithium or  valproic  acid  up-regulated
cell  surface  NaV1.7  Na+  channel  via  acceleration  of  Na+  channel  α-subunit  gene  tran‐
scription,  thereby  resulting  in  the  enhancement  of  Na+  influx,  Ca2+  channel  gating  and
catecholamine  secretion  (Yamamoto  et  al.,  1996,  1997;  Yanagita  et  al.,  2009,  2011).
Chronic  insulin  treatment  also  up-regulated tau protein  via  acceleration of  protein  syn‐
thesis,  and induced neurite-like process  outgrowth (Nemoto et  al.,  2011).
In  addition  to  these  physiological  effects  of  insulin,  chronic  insulin  treatment  down-
regulated  cell  surface  density  of  insulin  receptor  via  reduction  of  insulin  receptor
mRNA stability  (Yokoo et  al.,  2007),  and protein  levels  of  IRS-1  and IRS-2  via  regulat‐
ing proteasomal  degradation and/or  synthesis  of  IRS-1  and IRS-2  (Nemoto et  al.,  2006).
These  insulin-induced  negative  feedback  regulations  of  insulin  receptor  and  IRS-1/-2
were  mimicked  by  treatment  with  potent  GSK-3  inhibitors  (lithium,  valproic  acid,  or
SB216763)  (Nemoto  et  al.,  2006,  2009;  Yokoo  et  al.,  2007).  LiCl  (20  mM)  decreased  cell
surface  125I-insulin  binding  and  insulin  receptor  protein  levels  by  ~48%  in  a  time-de‐
pendent  manner.  LiCl  destabilized insulin receptor  mRNA (t1/2  =  9.3  vs.  6.5  h),  decreas‐
ing  insulin  receptor  mRNA  level  by  ~47%,  without  altering  insulin  receptor  gene
transcription  (Yokoo et  al.,  2007).  LiCl  also  decreased protein  levels  of  IRS-1  and IRS-2
by  ∼38  and  ∼48% in  a  concentration-  and  time-dependent  manner.  Proteasome inhibi‐
tors  (β-lactone  or  lactacystin)  completely  blocked  LiCl-induced  reduction  of  IRS-1,  and
partially  blocked  LiCl-induced  reduction  of  IRS-2.  LiCl  lowered  IRS-2  mRNA  level,
with  no effect  on IRS-1  mRNA level  (Nemoto et  al.,  2006).  These  findings  suggest  that
long-term  treatment  with  insulin,  lithium  or  valproic  acid  causes  negative  feedback
regulation  of  insulin  receptor  signaling  via  inhibition  of  GSK-3,  thereby  withdrawal  of
these  therapeutic  drugs  after  long-term treatment  may occurs  severe  depletion  of  insu‐
lin signaling.
8. Conclusion and future perspectives
Multiple  lines  of  experiments  in  the  last  two  decades  have  accumulated  compelling
evidence that  brain insulin receptor  signaling plays  pivotal  roles  in  regulating brain re‐
gion-specific  pleiotropic  function,  including  cognitive  and  mood  stabilizing  function.
Aberrant  decrease  in  brain  insulin  receptor  signaling  (e.g.  insulin  resistance)  may  be
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involved in  the  various  cognitive  and mood disorder.  There  are  two major  approaches
to  improve  insulin  signal  impairment:  1)  stimulation  of  insulin  receptor  signaling  by
insulin  such  as  intranasal  administration  of  insulin  and 2)  adjustment  of  insulin  recep‐
tor  signaling  via  modulation  of  expression  and  function  of  insulin  receptor  signaling
molecules.  The  information  of  up-  and  down-regulation  of  insulin  receptor  signaling
by various  therapeutic  drugs  may provide  a  new avenue  for  the  prevention  and treat‐
ment of  neurodegenerative disease,  dementia  and mood disorders.
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